Table 2.
Clinical Characteristics of Participants With Human Immunodeficiency Virus
| Clinical Characteristic (n = 127) | Frequency, n (%) |
|---|---|
| Human immunodeficiency virus treatment status at baseline | |
| Naive | 68 (53.5) |
| On ART | 59 (46.5) |
| World Health Organization immunological classificationa (n = 88) | |
| Not significant | 21 (24.4) |
| Mild | 8 (9.3) |
| Advanced | 8 (9.3) |
| Severe | 49 (57.0) |
| CD4 count (n = 95), cell/mm3 | |
| <200 | 19 (20.0) |
| ≥200–350 | 10 (10.5) |
| ≥350–500 | 7 (7.4) |
| ≥500 | 59 (62.1) |
| CD4% (n = 86) | |
| <15 | 34 (39.5) |
| ≥15 | 52 (60.5) |
| ART regimen (n = 116) | |
| Efavirenz-based | 60 (51.7) |
| Lopinavir-based | 43 (37.1) |
| Nevirapine-based | 13 (11.2) |
Abbreviation: ART, antiretroviral therapy.
aWorld Health Organization case definitions of human immunodeficiency virus (HIV) for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children [25].